January 11, 2010 - Reirradiation using fractionated stereotactic radiosurgery (SRS) after previous radiotherapy for head-and-neck cancer is feasible, concluded researchers a study published in the Official Journal of the American Society for Radiation Oncology.

The researchers wanted to find the feasibility of stereotactic radiosurgery (SRS) because it “is an appealing treatment option after previous radiotherapy because of its precision, conformality, and reduced treatment duration.”

From 2002 to 2008, 65 patients received SRS to the oropharynx (13), hypopharynx (8), nasopharynx (7), paranasal sinus (7), neck (7), and other sites (23). Thirty-eight patients were treated definitively and 27 patients with metastatic disease and/or untreated local disease were treated palliatively. Nine patients underwent complete macroscopic resection before SRS. Thirty-three patients received concurrent chemoradiation. The median initial radiation dose was 67 Gy, and the median reirradiation SRS dose was 30 Gy (21–35 Gy) in 2–5 fractions.

Follow-up was on average 16 months for surviving patients. Fifty-six patients were evaluable for response: 30 (54 percent) had complete, 15 (27 percent) had partial, and 11 (20 percent) had no response. The overall survival (OS) for all patients averaged 12 months. For definitively treated patients, the 2-year OS and locoregional control (LRC) rates were 41 percent and 30 percent, respectively. Multivariate analysis demonstrated that higher total dose, surgical resection, and nasopharynx site were significantly associated with improved LRC; surgical resection and nonsquamous histology were associated with improved OS. Seven patients (11 percent) experienced severe reirradiation-related toxicity, including one treatment-attributed death.

Researchers concluded their findings showing SRS reirradiation for head-and-neck cancer a feasible demonstrated encouraging response rates with acceptable toxicity.

But they cautioned, “Fractionated SRS reirradiation with concurrent chemotherapy in select patients warrants further study.”

Reference: Unger, M.D., K.; Lominska, M.D., C.; Deeken, M.D., J.; et al. Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. doi:10.1016/j.ijrobp.2009.06.070

For more information: www.redjournal.org


Related Content

News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
Feature | Radiology Business

ITN conducts a bi-monthly survey to its readers on a variety of topics, which is used to create the Last Read, a unique ...

Time July 08, 2024
arrow
Subscribe Now